Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial - Wikidata - awgldk - TriplyDB

Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial

Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial

http://www.wikidata.org/entity/Q33699901

about

Targeted therapy of gastrointestinal stromal tumours The GIST of targeted therapy for malignant melanoma Medical management of metastatic medullary thyroid cancer Key messages from the BFR14 trial of the French Sarcoma Group.Early outcomes of exon 11 mutants in GIST treated with standard dose Imatinib.Practical aspects of risk assessment in gastrointestinal stromal tumors.Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib.External beam radiation therapy for locally advanced and metastatic gastrointestinal stromal tumors.Lessons learned from the study of 10,000 patients with soft tissue sarcoma.The efficacy of adjuvant imatinib therapy in improving the prognosis of patients with colorectal gastrointestinal stromal tumours.Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion.Treatment and Prognoses in Patients With Primary Gastrointestinal Stromal Tumors ≥10 cm: A Single-Institution Experience in China.Laparoscopic Versus Open Resection of Small Bowel Gastrointestinal Stromal Tumors: Systematic Review and Meta-Analysis.Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor.How best to manage gastrointestinal stromal tumor.Gastrointestinal stromal tumours: from KIT to succinate dehydrogenase.Gastrointestinal stromal tumors: who should get imatinib and for how long?Managing GIST in the imatinib era: optimization of adjuvant therapy.Late hepatic metastasis from a duodenal gastrointestinal stromal tumor (29 years after surgery): report of a case and review of the literature.A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.The Role of Surgery in Metastatic Gastrointestinal Stromal Tumors.Current Standard and Future Perspectives in the Treatment of Gastrointestinal Stromal Tumors.Principles of Kinase Inhibitor Therapy for Solid Tumors.Incorporation of NLR into NIH stratification system increases predictive accuracy for surgically resected gastrointestinal stromal tumors.Is multivisceral resection in locally advanced gastrointestinal stromal tumours an acceptable strategy?Considering the role of radiation therapy for gastrointestinal stromal tumor Gastric and small intestine gastrointestinal stromal tumors: Do outcomes differ?A Phase 2 Study of the Hsp90 Inhibitor AUY922 as Treatment for Patients with Refractory Gastrointestinal Stromal Tumors.Current research and treatment for gastrointestinal stromal tumors.Surgery for gastrointestinal stromal tumors (GISTs) of the stomach and small bowel: short- and long-term outcomes over three decades.Dermatofibrosarcoma protuberans and gastrointestinal stromal tumor as models for targeted therapy in soft tissue sarcomas.Role of immune microenvironment in gastrointestinal stromal tumours.Genotype and risk of tumour rupture in gastrointestinal stromal tumour.Long-term Results of Adjuvant Imatinib Treatment for Localized Gastrointestinal Stromal Tumors after Surgery Patient-derived organoid models help define personalized management of gastrointestinal cancer.Management of hemorrhage in gastrointestinal stromal tumors: a review.Clinicopathological Features and Prognosis of Primary GISTs with Tumor Rupture in the Real World.Gastrointestinal stromal tumors: A multidisciplinary challenge.Prognostic Analysis of Duodenal Gastrointestinal Stromal Tumors.Advances and Challenges on Management of Gastrointestinal Stromal Tumors.

P2860

Q26745633-C0BD22F9-3A09-4B1D-801D-1D7CFFDE22FF Q26827092-8CB52697-CDB1-4EEF-B82E-DD2239D4DF81 Q27005897-178B271E-AA2F-4F48-A5D0-CDE7ABD4EA6C Q30245384-9945A0CD-7162-4909-8B79-9E899F87337E Q33575310-1E253B95-A595-4C28-A19C-244F1FE2A7D4 Q34021413-3487EBB0-499E-4538-AA04-8B5FB23D2410 Q34407270-87AEFC3B-3A61-4588-A066-B1DB3BA51D5C Q34461532-4D658257-24D8-4637-88F4-EDF90483BE44 Q34663883-E672F32B-DE49-41C1-826E-ADC149D6D886 Q35759790-58589985-2195-42B1-84C7-177C0B2FEC55 Q35820539-4538AB0E-9817-4863-A64B-1FF5853084F1 Q36196622-94F32400-8A1B-46D7-9F4A-C28AC94C96A3 Q36412090-E905B8D6-FB9B-4847-8717-2816BF874A66 Q37705793-547E3143-5591-49B5-9AD7-88C5D20E5E73 Q37743051-9D74C985-71A1-4BC4-BC17-B5A90C449D1E Q38151827-D91EC880-1227-4F2B-8642-9277A25C5751 Q38257940-C1B422E8-00D3-4EDE-9057-04FE5B83EDF5 Q38262193-640E8DA9-082D-4893-8301-9C6615169C19 Q38365761-0D78F6A8-8398-43D0-A391-87EEFCB289C4 Q38584379-C361D42E-29C2-46BF-BA3C-A4A075E71575 Q38714790-23CD1114-9296-469D-98BF-6CE8FEB32448 Q38734000-A017BB81-9A82-4D0F-9970-229557A20E55 Q38802154-6E55505E-09C0-462C-BEED-B23A4383BBA7 Q39049191-7ABD775C-C1E7-4D13-8970-D6E28C1FE643 Q39735609-B664B9EC-5089-42A3-9E3B-38472800E5DF Q39754896-ACC8DA5A-5C83-4C2E-913A-BF27468EA203 Q40457832-A5524E8B-6E60-4C33-A5C9-8B5894A6DF4E Q40666673-950E5BE4-342F-4487-87E7-1AC72F8F6286 Q42337115-7E30D082-2E4E-44B5-B364-C4090CC92F97 Q44840077-89D40F7D-87C7-4147-9878-0FA9F341A010 Q47681398-206F189C-409C-4562-95C7-34AAFFD752B9 Q47856440-FB083D8A-CA46-47E0-963C-38C31D075BBE Q48229455-B493D871-BA9E-4AE9-A59D-97BD48C2B527 Q49648852-A2FE6743-5BDD-4389-B2EC-C93E221A5192 Q50010294-DB75DF53-8DD9-49B5-8FFF-B3A40124AF61 Q52562706-CE4894A0-4279-41C7-B767-E21D6285599E Q53822324-43B43E51-26D0-4F74-A812-F7ABBDEFEC4C Q54964592-24965BC1-8B07-47B4-897E-E7A7B649348D Q55038772-25FE3949-178E-4F27-8453-BD598D84E8E6 Q55263134-05808E99-0FE1-4B01-B759-3682DBA5509C

P2860

Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial

http://www.wikidata.org/entity/Q33699901

description

2013 nî lūn-bûn

@nan

2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Long-term results of adjuvant ...... ance) intergroup phase 2 trial

@ast

Long-term results of adjuvant ...... ance) intergroup phase 2 trial

@en

type

label

Long-term results of adjuvant ...... ance) intergroup phase 2 trial

@ast

Long-term results of adjuvant ...... ance) intergroup phase 2 trial

@en

prefLabel

Long-term results of adjuvant ...... ance) intergroup phase 2 trial

@ast

Long-term results of adjuvant ...... ance) intergroup phase 2 trial

@en

P1433

Q33699901-1523C5D4-C121-404E-A75E-5113DFAE6A7D

P1476

Q33699901-80FC3F51-E9F3-46C8-B0F8-0B7142CF6334

P2093

Q33699901-0B071873-23B5-4168-8233-9A71E2606E9D

Q33699901-1F83155F-BA18-46C9-A5B4-AC2A3A224A5D

Q33699901-3F668555-47E8-4115-9718-4D33CE43DFAB

Q33699901-623701FD-32B5-434B-BCFC-A0ABC557CACC

Q33699901-7C5DE9EA-5FA3-4E43-AE0C-F57D645383A7

Q33699901-830F00B1-8970-4D6F-8845-4AD9D52E588E

Q33699901-88BC2F24-2533-4D9A-ABA3-E3CAEA58F70A

Q33699901-C123CB70-B886-40EB-84C2-51C8D0FBF4CF

Q33699901-C48CCF4D-6297-4B52-ADC7-B73EE0D9B019

Q33699901-E071CB6D-725D-42D7-A247-D58C718C76B2

P2860

Q33699901-1A414C60-95B8-4BE0-ABC9-5C24EECE7459

Q33699901-1EC64E97-EA7A-491C-A9FB-893264AFCA6D

Q33699901-21DB04D5-C819-48D4-AC8D-E049B53C43FE

Q33699901-4E89369C-C31D-4A84-93AA-72AD4CB59EC4

Q33699901-4F344601-D170-40C1-9C64-15B30A32C8F4

Q33699901-6013AF30-DC47-4A4B-8D05-0B5EC1ED153E

Q33699901-721701BF-0AF3-424D-956B-19B1700EDF20

Q33699901-84489746-394C-4CEF-B898-7B1967BDEEFC

Q33699901-84EB86A5-6413-4764-B162-F17D659FA300

Q33699901-8D6DB86F-34A1-451D-B7CA-8767FA98FE67

P304

Q33699901-186BD6EA-DC10-4A57-AE48-1E82FADB1165

P31

Q33699901-53DC61D1-A785-440A-B6E5-C8926DB3AD78

P356

Q33699901-D3BFD9BF-F6A9-48D5-92DB-7EAAF46142E3

P407

Q33699901-1946DC76-04F9-4D54-86E6-31717231DDE3

P433

Q33699901-C0D38CFA-4F69-46B9-993C-AC0C59982C28

P478

Q33699901-6E999013-1E62-4247-A7ED-1779581F5BC3

P50

Q33699901-431034E2-3C27-45A0-8BE0-CC57DEBF7D76

Q33699901-6A49264E-5902-45C1-9C2B-4D3E90AB231C

Q33699901-A281DCA1-4094-4122-8973-88BB0F8616F4

P577

Q33699901-A394E4A9-63D2-4D3F-8CB2-833A1C62BA70

P698

Q33699901-282A928C-1872-44EC-9F8B-5C7A6DBEBAC5

P921

Q33699901-5B0CD42D-3C83-4B82-82FB-180805DD9289

P932

Q33699901-9B887192-530C-48B6-B516-8E450203D176

P356

SLA.0B013E3182A15EB7

P1433

Annals of Surgery

P1476

Long-term results of adjuvant ...... ance) intergroup phase 2 trial

@en

P2093

American College of Surgeons O ...... or Clinical Trials in Oncology

http://www.w3.org/2001/XMLSchema#string

Christopher Corless

http://www.w3.org/2001/XMLSchema#string

Cristina R Antonescu

http://www.w3.org/2001/XMLSchema#string

George D Demetri

http://www.w3.org/2001/XMLSchema#string

Jeffrey Norton

http://www.w3.org/2001/XMLSchema#string

Kouros Owzar

http://www.w3.org/2001/XMLSchema#string

Margaret von Mehren

http://www.w3.org/2001/XMLSchema#string

Martin D McCarter

http://www.w3.org/2001/XMLSchema#string

Peter W T Pisters

http://www.w3.org/2001/XMLSchema#string

Ronald P DeMatteo

http://www.w3.org/2001/XMLSchema#string

P2860

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis

Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients.

PDGFRA activating mutations in gastrointestinal stromal tumors.

Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

Clinical management of gastrointestinal stromal tumors: before and after STI-571.

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.

P304

422-429

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/SLA.0B013E3182A15EB7

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

258

http://www.w3.org/2001/XMLSchema#string

P50

Karla V Ballman

P577

2013-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23860199

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

4041735

http://www.w3.org/2001/XMLSchema#string